These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 24857147)

  • 1. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications.
    Jimenez CR; Verheul HM
    Am Soc Clin Oncol Educ Book; 2014; ():e504-10. PubMed ID: 24857147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies in functional proteomics: Unveiling the pathways to precision oncology.
    Favicchio R; Thepaut C; Zhang H; Arends R; Stebbing J; Giamas G
    Cancer Lett; 2016 Nov; 382(1):86-94. PubMed ID: 26850375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic Approaches for Biomarker Panels in Cancer.
    Tanase C; Albulescu R; Neagu M
    J Immunoassay Immunochem; 2016; 37(1):1-15. PubMed ID: 26565430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical proteomics in cancer: Where we are.
    Panis C; Pizzatti L; Souza GF; Abdelhay E
    Cancer Lett; 2016 Nov; 382(2):231-239. PubMed ID: 27561426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease.
    Smith JG; Gerszten RE
    Circulation; 2017 Apr; 135(17):1651-1664. PubMed ID: 28438806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer.
    Murray HC; Dun MD; Verrills NM
    Expert Opin Drug Discov; 2017 May; 12(5):431-447. PubMed ID: 28286965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer proteomics: developments in technology, clinical use and commercialization.
    Yeat NC; Lin C; Sager M; Lin J
    Expert Rev Proteomics; 2015 Aug; 12(4):391-405. PubMed ID: 26145529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncoproteomics: Trials and tribulations.
    Zhou L; Li Q; Wang J; Huang C; Nice EC
    Proteomics Clin Appl; 2016 Apr; 10(4):516-31. PubMed ID: 26518147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introduction: Cancer Gene Networks.
    Clarke R
    Methods Mol Biol; 2017; 1513():1-9. PubMed ID: 27807826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.
    Wang J; Mouradov D; Wang X; Jorissen RN; Chambers MC; Zimmerman LJ; Vasaikar S; Love CG; Li S; Lowes K; Leuchowius KJ; Jousset H; Weinstock J; Yau C; Mariadason J; Shi Z; Ban Y; Chen X; Coffey RJC; Slebos RJC; Burgess AW; Liebler DC; Zhang B; Sieber OM
    Gastroenterology; 2017 Oct; 153(4):1082-1095. PubMed ID: 28625833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput proteomics and AI for cancer biomarker discovery.
    Xiao Q; Zhang F; Xu L; Yue L; Kon OL; Zhu Y; Guo T
    Adv Drug Deliv Rev; 2021 Sep; 176():113844. PubMed ID: 34182017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging applications for phospho-proteomics in cancer molecular therapeutics.
    Moran MF; Tong J; Taylor P; Ewing RM
    Biochim Biophys Acta; 2006 Dec; 1766(2):230-41. PubMed ID: 16889898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Proteomic Analysis of Differentially Expressed Protein Profiles Involved in Pancreatic Ductal Adenocarcinoma.
    Kuo KK; Kuo CJ; Chiu CY; Liang SS; Huang CH; Chi SW; Tsai KB; Chen CY; Hsi E; Cheng KH; Chiou SH
    Pancreas; 2016 Jan; 45(1):71-83. PubMed ID: 26262590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer biomarker discovery and translation: proteomics and beyond.
    Hristova VA; Chan DW
    Expert Rev Proteomics; 2019 Feb; 16(2):93-103. PubMed ID: 30556752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery.
    Jimenez CR; Piersma S; Pham TV
    Biomark Med; 2007 Dec; 1(4):541-65. PubMed ID: 20477373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass spectrometry based translational proteomics for biomarker discovery and application in colorectal cancer.
    Ma H; Chen G; Guo M
    Proteomics Clin Appl; 2016 Apr; 10(4):503-15. PubMed ID: 26616366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomics in cancer screening and management in gynecologic cancer.
    Hu W; Wu W; Kobayashi R; Kavanagh JJ
    Curr Oncol Rep; 2004 Nov; 6(6):456-62. PubMed ID: 15485615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of cancer drug resistance mechanisms by phosphoproteomics.
    Boulos JC; Yousof Idres MR; Efferth T
    Pharmacol Res; 2020 Oct; 160():105091. PubMed ID: 32712320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.